Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1997 1
1998 2
1999 1
2000 3
2001 7
2002 3
2003 2
2004 2
2005 3
2006 6
2007 3
2008 1
2009 4
2010 1
2011 1
2012 1
2013 1
2014 1
2015 5
2016 2
2018 7
2019 1
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Bortezomib-induced skin lesion.
Ozcan MA, Alacacioglu I, Piskin O, Lebe B, Turgut N, Ceneli S, Demirkan F, Ozsan GH, Undar B. Ozcan MA, et al. Among authors: undar b. Acta Haematol. 2006;116(3):226-7. doi: 10.1159/000094689. Acta Haematol. 2006. PMID: 17016047 No abstract available.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Robak T, et al. N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. N Engl J Med. 2015. PMID: 25738670 Free article. Clinical Trial.
Platelet activation in congenital heart diseases.
Olgun N, Uysal KM, Irken G, Unal N, Undar B, Akkoç N, Akçoral A, Sarialioğlu F, Cevik N. Olgun N, et al. Among authors: undar b. Acta Paediatr Jpn. 1997 Oct;39(5):566-9. doi: 10.1111/j.1442-200x.1997.tb03642.x. Acta Paediatr Jpn. 1997. PMID: 9363654
IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort.
Sevindik OG, Mersin S, Katgi A, Tunali S, Solmaz SM, Acar C, Alacacioglu I, Piskin O, Ozcan MA, Demirkan F, Undar B, Ozsan GH. Sevindik OG, et al. Among authors: undar b. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e101-4. doi: 10.1016/j.clml.2015.02.004. Epub 2015 Feb 11. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25790738
62 results